CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 24.06%. A quarter ago, it was expected that this company would post a loss of $1.37 per share when it actually produced a loss of $1.49, delivering a surprise of -8.76%.Over the last four quarters, the company has s ...

财务状况 - 公司2021年第四季度营收为1.38亿美元，同比增长18%。[1] - 公司2021年全年营收为5.04亿美元，同比增长22%。[1] - 公司2021年第四季度毛利率为78.5%，同比提高1.5个百分点。[1] - 公司2021年全年毛利率为77.9%，同比提高1.1个百分点。[1] 业务发展 - 公司在2021年第四季度新增了超过1,000家付费客户，总付费客户数达到约15,000家。[1] - 公司在2021年全年新增了超过4,000家付费客户。[1] - 公司在2021年第四季度新增了超过100家大型企业客户，总大型企业客户数达到约1,000家。[1] - 公司在2021年全年新增了超过300家大型企业客户。[1] 未来展望 - 公司预计2022年第一季度营收将达到1.38亿至1.40亿美元，同比增长约15%至17%。[1] - 公司预计2022年全年营收将达到5.80亿至5.90亿美元，同比增长约15%至17%。[1] - 公司将继续专注于产品创新和客户服务,以推动未来增长。[1]

产品管线 - CASGEVY™已获得瑞士和加拿大批准用于12岁及以上患有镰状细胞病和输血依赖性β地中海贫血的患者[3] - 针对CD19的下一代CAR T产品候选物CTX112™正在进行两项临床试验,用于B细胞恶性肿瘤和系统性红斑狼疮[5][11] - 针对CD70的下一代CAR T产品候选物CTX131™正在进行两项临床试验,用于实体瘤和血液恶性肿瘤[5] - 针对ANGPTL3和LPA的体内基因编辑产品候选物CTX310™和CTX320™正在进行临床试验[6] - 针对1型糖尿病的同种异体、低免疫原性、基因编辑干细胞衍生产品候选物CTX211™正在进行1期临床试验[7] - CRISPR Therapeutics正在开发CTX131,这是一种针对CD70抗原的下一代同种异体CAR T产品候选药物,可用于治疗实体瘤和血液恶性肿瘤,包括T细胞淋巴瘤[12] - CTX211是一种同种异体、基因编辑的干细胞衍生的1型糖尿病治疗候选药物,正在进行1期临床试验[14] 商业合作 - 公司建立了与拜耳和辉瑞的战略合作关系[15] 财务状况 - 截至10月中旬,全球已有45个授权治疗中心启用,约40名患者已进行细胞采集[3] - 公司现金、现金等价物和有价证券约为19.356亿美元[8] - 截至2024年9月30日,CRISPR Therapeutics的现金及现金等价物为22,567万美元,有价证券为17.1亿美元[20] - 截至2024年9月30日,CRISPR Therapeutics的总资产为22.56亿美元,股东权益为19.40亿美元[20] 未来计划 - 公司计划在2024年美国血液学会年会上提供CTX112在B细胞恶性肿瘤1期剂量递增研究的更新[5] - CRISPR Therapeutics建立了一个专有的脂质纳米颗粒(LNP)平台,用于将CRISPR/Cas9递送到肝脏,其体内项目包括针对ANGPTL3和LPA的候选药物CTX310和CTX320,正在针对高胆固醇血症和高脂蛋白(a)进行临床试验[13]

公司产品研发进展 - CASGEVY在瑞士和加拿大被批准用于12岁及以上镰状细胞病和输血依赖性β地中海贫血患者的治疗全球已有45个授权治疗中心被激活 截至10月中旬约有40名患者进行了细胞采集 [1][3] - 下一代CAR T产品候选物CTX112针对B细胞恶性肿瘤和系统性红斑狼疮的两项临床试验正在进行中 [1] - 下一代CAR T产品候选物CTX131针对实体肿瘤和血液恶性肿瘤的两项临床试验正在进行中 [1] - 体内基因编辑产品候选物CTX310和CTX320的临床试验正在进行中 [1] - CTX211用于治疗1型糖尿病的临床试验正在进行中 [1] 公司财务状况 - 截至2024年9月30日公司拥有约19亿美元现金现金等价物和有价证券 [1] - 2024年第三季度研发费用为8220万美元较2023年第三季度减少主要由于外部研究和制造成本降低 [7] - 2024年第三季度一般和管理费用为1740万美元较2023年第三季度减少 [7] - 2024年第三季度合作费用净额为1120万美元较2023年第三季度减少 [7] - 2024年第三季度净亏损为8590万美元较2023年第三季度减少 [7]

It won't be able to be profitable without hitting its targets for both of these figures.Biotechs like CRISPR Therapeutics (CRSP 9.42%) can be tricky to invest in, as it isn't always obvious whether management's plans are working or not. Simply focusing on a big-picture figure like revenue often misses key points about what the company has done and where it's going.On that note, CRISPR's Q3 earnings will be reported sometime between Nov. 4 and Nov. 8 at the latest. When those results come out, investors shou ...

We expect CRISPR Therapeutics (CRSP) to surpass expectations when it reports third-quarter 2024 results. In the last reported quarter, the company missed on earnings by 8.76%. The Zacks Consensus Estimate for sales is pinned at $6.4 million, while the same for earnings is pegged at a loss of $1.33 per share. Factors Shaping CRSP's Upcoming Results CRISPR Therapeutics' top line currently includes grants and collaboration revenues from its partnership with large-cap biotech Vertex Pharmaceuticals (VRTX) . CRS ...

CRISPR Therapeutics (NASDAQ: CRSP ) is the market leader in transformative therapies incorporating CRISPR/Cas9 biotechnology, and their 9-year ongoing partnership with Vertex Pharmaceuticals ( VRTX ) brings great promise. Most recently, both companies received FDA (December 2023) and EMA (February 2024) approvals for Casgevy, the I have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the p ...

This company might be worth far more than many realize.If I had to buy one share of any biotech with no price restriction, I'd naturally gravitate toward the most successful companies in the industry. However, the exercise becomes more complicated if you stipulate a limit of $50 per share; most of the prominent biotech stocks are trading well above that amount.Those around that level are, disproportionately, relatively small and risky companies whose prospects don't look all that strong. Still, at least one ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, marking a -0.84% move from the previous day. This change lagged the S&P 500's daily loss of 0.18%. Elsewhere, the Dow saw a downswing of 0.8%, while the tech-heavy Nasdaq appreciated by 0.27%.The the stock of company has risen by 1.54% in the past month, leading the Medical sector's loss of 3.03% and undershooting the S&P 500's gain of 4.46%.Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its u ...

文章核心观点 - 分析师给予CRISPR Therapeutics AG (CRSP)股票的平均目标价为81.96美元,较当前价格上涨67.5%,表明该股票存在较大上涨潜力 [1] - 分析师对公司未来盈利前景持乐观态度,这可能是该股票有望上涨的合理原因 [5] - 尽管分析师的目标价格可能存在偏高的倾向,但分析师预测一致性较高仍可作为进一步研究的出发点 [4] 根据相关目录分别进行总结 分析师目标价格 - 分析师给予CRSP股票的平均目标价为81.96美元,较当前价格上涨67.5% [1] - 分析师目标价格范围从30美元到199美元不等,标准差为34.57美元 [1] - 最乐观的目标价格预测公司股价可上涨306.8% [1] 分析师预测一致性 - 分析师对公司未来盈利前景普遍持乐观态度,这可能是该股票有望上涨的合理原因 [5] - 过去30天内,公司当年盈利预测值上调0.5%,反映分析师预测一致性较高 [5] - 分析师预测一致性较高,可作为进一步研究的出发点,但不应完全依赖目标价格做出投资决策 [4] 分析师预测偏差 - 分析师设置的目标价格往往存在偏高的倾向,可能源于其所在机构的商业利益考虑 [3] - 尽管分析师对公司基本面和行业敏感性有深入了解,但其预测结果往往令投资者失望 [3] - 投资者不应完全依赖分析师的目标价格做出投资决策,而应保持谨慎态度 [4]